Data Insights

CHM-2101 by Chimeric Therapeutics for Colorectal Cancer: Likelihood of Approval

CHM-2101 is under clinical development by Chimeric Therapeutics and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - CHM-2101 in Colorectal Cancer

Data Insights

CHM-2101 by Chimeric Therapeutics for Colon Cancer: Likelihood of Approval

CHM-2101 is under clinical development by Chimeric Therapeutics and currently in Phase II for Colon Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - CHM-2101 in Colon Cancer

Data Insights

CHM-2101 by Chimeric Therapeutics for Pancreatic Cancer: Likelihood of Approval

CHM-2101 is under clinical development by Chimeric Therapeutics and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - CHM-2101 in Pancreatic Cancer

Data Insights

CHM-2101 by Chimeric Therapeutics for Gastric Cancer: Likelihood of Approval

CHM-2101 is under clinical development by Chimeric Therapeutics and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - CHM-2101 in Gastric Cancer

Data Insights

CHM-2101 by Chimeric Therapeutics for Rectal Cancer: Likelihood of Approval

CHM-2101 is under clinical development by Chimeric Therapeutics and currently in Phase II for Rectal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - CHM-2101 in Rectal Cancer

Data Insights

CHM-2101 by Chimeric Therapeutics for Neuroendocrine Tumors: Likelihood of Approval

CHM-2101 is under clinical development by Chimeric Therapeutics and currently in Phase II for Neuroendocrine Tumors. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - CHM-2101 in Neuroendocrine Tumors